Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May 1:1207:225-36.
doi: 10.1016/j.brainres.2008.01.095. Epub 2008 Feb 16.

Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice

Affiliations

Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice

Ann C McKee et al. Brain Res. .

Abstract

We examined the effects of ibuprofen on cognitive deficits, Abeta and tau accumulation in young triple transgenic (3xTg-AD) mice. 3xTg-AD mice were fed ibuprofen-supplemented chow between 1 and 6 months. Untreated 3xTg-AD mice showed significant impairment in the ability to learn the Morris water maze (MWM) task compared to age-matched wild-type (WT) mice. The performance of 3xTg-AD mice was significantly improved with ibuprofen treatment compared to untreated 3xTg-AD mice. Ibuprofen-treated transgenic mice showed a significant decrease in intraneuronal oligomeric Abeta and hyperphosphorylated tau (AT8) immunoreactivity in the hippocampus. Confocal microscopy demonstrated co-localization of conformationally altered (MC1) and early phosphorylated tau (CP-13) with oligomeric Abeta, and less co-localization of oligomeric Abeta and later forms of phosphorylated tau (AT8 and PHF-1) in untreated 3xTg-AD mice. Our findings show that prophylactic treatment of young 3xTg-AD mice with ibuprofen reduces intraneuronal oligomeric Abeta, reduces cognitive deficits, and prevents hyperphosphorylated tau immunoreactivity. These findings provide further support for intraneuronal Abeta as a cause of cognitive impairment, and suggest that pathological alterations of tau are associated with intraneuronal oligomeric Abeta accumulation.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Comparison of MWM performance among 3×Tg-AD mice, ibuprofen-treated 3×Tg-AD mice and WT mice
Asterisks denote significant differences with respect to WT mice at a p < 0.05 level. Error bars indicate SEM A. Six month old ibuprofen-treated 3×Tg-AD mice learned the MWM task at the same rate as age-matched WT mice reaching the pre-set criteria for learning (mean latency <25 s) on the same day (Day 4). On Day 6 and 7 WT mice reached the platform with decreasing escape latencies (escape latency of <10 s on Day 7) while ibuprofen-treated 3×Tg-AD mice maintain their escape latency around 25 s. Untreated six month old 3×Tg-AD mice were unable to learn the MWM task, as their escape latency did not progressively decreased during the 7 consecutive days of training. On the other hand, untreated two month old 3×Tg-AD mice perform similar to 6 month WT mice. B, C and D. Probe analysis performed on day 4 (1.5 h after training day 4) and day 5 (24 h after training day 4). Ibuprofen-treated 3×Tg-AD mice spent as much time as WT mice swimming in the quadrant where the platform was supposed to be at both 1.5 and 24 h probe. While WT mice improved their performance at the 24 h probe compared to the 1.5 h probe (increased the number of platform location crosses and decreased the latency to cross the platform location), ibuprofen-treated 3×Tg-AD mice did not. Untreated 3×Tg-AD mice performed significantly worse than WT mice based on the number of platform location crosses and the latency to cross the platform location at the 24 h probe test.
Figure 2
Figure 2. Sections of hippocampus CA1 and subiculum immunostained for Aβ
A. Six month wild-type mouse shows no immunoreactivity for 6E10 in CA1 near the subiculum, B. Untreated 2 month 3×Tg-AD mouse shows scant granular immunoreactivity for NU-1 in the perikarya of CA1 neurons C. D. Untreated 6 month 3×Tg-AD mouse shows intense immunoreactivity for NU-1 in the perikarya of CA1 and subicular neurons. E. F. Ibuprofen treated 6 month 3×Tg-AD mouse shows markedly reduced immunoreactivity for NU-1 in the same region. A,B,D,F : Original magnification × 300, C,E: Original magnification × 38.
Fig. 3
Fig. 3. Sections of hippocampal CA1 neurons immunostained for MC1 and CP-13
A.B. Untreated 6 month 3×Tg-AD mouse shows intense immunoreactivity for diffuse MC1 in the perikarya extending into the apical dendrite, A. Original magnification × 150, B. Occasional neurons show intense granular staining for MC1 in the perikaryon, as well as diffuse dendritic staining, original magnification × 945. C. D. Ibuprofen treated 6 month 3×Tg-AD mouse shows nearly absent immunoreactivity for MC1, C. Original magnification × 150, D. Original magnification × 945. E. F. Untreated 6 month 3×Tg-AD mouse shows intense immunoreactivity for finely granular CP-13 in the perikarya extending into the apical dendrites and dendritic arbors. E. Original magnification × 150, F. Original magnification × 945. G. H. Ibuprofen treated 6 month 3×Tg-AD mouse shows marked reduction in immunoreactivity for CP-13, immunoreactivity is primarily dendritic G. Original magnification × 150, H. Original magnification × 945.
Fig. 4
Fig. 4. Double immunostained sections of hippocampal CA1 neurons in untreated 6 month 3×Tg-AD mice
A. Double immunostained sections for NU-1 and MC1 show diffuse MC1 immunoreactivity (brown) extending into the apical dendrite of neurons with granular perikaryal NU-1 (red, asterisks), original magnification × 945. B. Double immunostained sections for NU-1 and CP-13 shows diffuse CP-13 immunoreactivity (brown) extending into the apical dendrite of neurons with granular perikaryal NU-1 (red, asterisks), original magnification × 945. C. Double immunostained sections for NU-1 and AT8 shows granular AT8 immunoreactivity (brown) in occasional neurons, while neighboring neurons show granular perikaryal NU-1 (red, asterisk), original magnification × 945. D. Double immunostained sections for NU-1 and PHF-1 shows dense aggregates of PHF-1 immunoreactivity (brown) in the perikaryon and dendrite of occasional neurons, while neighboring neurons show granular perikaryal NU-1 (red, asterisk), original magnification × 945. E. Double immunostained sections for NU-1 and CP-13 show diffuse CP-13 immunoreactivity (brown) extending into the apical dendrites and lush dendritic arbors of neurons with granular perikaryal NU-1 (red, asterisks), original magnification × 945.
Fig. 5
Fig. 5. Sections of CA1 hippocampus from untreated 6 month 3×Tg-AD mouse shows neurons immunoreactive for AT8
A. Original magnification × 150, B. Original magnification × 945.
Figure 6
Figure 6. THE co-localization of tau and NU-1 using confocal microscopy in 6 month untreated 3×Tg-AD mice
The co-localization intensity of tau [stained with MC1 (a) (green), CP13 (f) (green), AT8 (k) (green), and PHF1 (p) (green)] and NU-1 (b, g, I, and q) (red) were determined by Disk Confocal Microscopy (Olympus, Tokyo, Japan) and the line measurement (AQI-X-COMBO-CWF, MediaCybernetics Inc. Bethesda, MD). The image analysis data shown in panel e, j, o, and t demonstrate the strong co-localization of NU1 with MC1 and CP13 and less co-localization with AT8 and PHF1. Scale bar: 10 mm.

Similar articles

Cited by

References

    1. Agdeppa ED, Kepe V, Petri A, Satyamurthy N, Liu J, Huang SC, Small GW, Cole GM, Barrio JR. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malono nitrile. Neuroscience. 2003;117:723–730. - PubMed
    1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383–421. - PMC - PubMed
    1. Barghorn S, Mandelkow E. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry. 2002;41:14885–14896. - PubMed
    1. Bayer TA, Wirths O, Majtenyi K, Hartmann T, Multhaup G, Beyreuther K, Czech C. Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol. 2001;11:1–11. - PMC - PubMed
    1. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675–688. - PubMed

Publication types

MeSH terms